Skip to main content

Good Start Genetics Expands Hopkins Aneuploidy Screening License to Enter NIPT Market

NEW YORK (GenomeWeb) – Good Start Genetics has expanded its exclusive license of an aneuploidy screening test and related know-how from Johns Hopkins University to include applications in noninvasive prenatal testing, the company said today.

Last December, Good Start Genetics licensed the approach, called FAST-SeqS for Fast Aneuploidy Screening Test-Sequencing System, for preimplantation genetic screening of embryos.

At the time, the company said that FAST-SeqS, which was developed by Hopkins researchers and published in 2012, may have applications beyond PGS, including prenatal testing.

Good Start Genetics President and CEO Don Hardison said in a statement that the company has been pleased with its early experience with FAST-SeqS for PGS and believes the technology and an ongoing collaboration with Hopkins researchers "offer great promise in NIPT, enabling easier workflows, lower costs and broader accessibility for patients."

FAST-SeqS uses a single primer pair to amplify distinct sections of the genome that occur on every chromosome and will be applied to maternal plasma DNA as part of a NIPT.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.